Saturday, December 24, 2011

 

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

BMJ 2011; 343 doi: 10.1136/bmj.d6333 (Published 31 October 2011)
Cite this as: BMJ 2011;343:d6333

  1. Correspondence to: D A Hughes d.a.hughes@bangor.ac.uk
  • Accepted 8 September 2011

Abstract

Objectives To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United Kingdom.

Design Quantitative benefit-harm and economic analyses using a discrete event simulation model to extrapolate the findings of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study to a lifetime horizon.

Setting UK National Health Service.

Population Cohorts of 50 000 simulated patients at moderate to high risk of stroke with a mean baseline CHADS2 (Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack) score of 2.1.

Main outcome measures Quality adjusted life years (QALYs) gained and incremental cost per QALY of dabigatran compared with warfarin.

Results Compared with warfarin, low dose and high dose dabigatran were associated with positive incremental net benefits of 0.094 (95% central range −0.083 to 0.267) and 0.146 (−0.029 to 0.322) QALYs. Positive incremental net benefits resulted for high dose dabigatran in 94% of simulations versus warfarin and in 76% of those versus low dose dabigatran. In the economic analysis, high dose dabigatran dominated the low dose, had an incremental cost effectiveness ratio of £23 082 (€26 700; $35 800) per QALY gained versus warfarin, and was more cost effective in patients with a baseline CHADS2 score of 3 or above. However, at centres that achieved good control of international normalised ratio, such as those in the UK, dabigatran 150 mg was not cost effective, at £42 386 per QALY gained.

Conclusions This analysis supports regulatory decisions that dabigatran offers a positive benefit to harm ratio when compared with warfarin. However, no subgroup for which dabigatran 110 mg offered any clinical or economic advantage over 150 mg was identified. High dose dabigatran will be cost effective only forpatients at increased risk of stroke or for whom international normalised ratio is likely to be less well controlled.

Introduction

Atrial fibrillation is the most common sustained cardiac arrhythmia, with an estimated prevalence in the United Kingdom of 10% in patients aged 75 or over and an associated fivefold increase in the risk of ischaemic stroke.1 2 Bed days for patients with a primary or secondary diagnosis of atrial fibrillation cost the National Health Service (NHS) £1.9bn (€2.2bn; $2.9bn) in 2008, with outpatient and other inpatient costs totalling £329m.3

Warfarin is the mainstay of oral thromboprophylactic anticoagulation treatment.4 However, patients show considerable variability in their response to warfarin, which, coupled with a narrow therapeutic range, necessitates frequent monitoring and adjustment of dosage to ensure optimal anticoagulation. Deviations outside the therapeutic range (international normalised ratio (INR) 2.0-3.0) increase the risk of both strokes and haemorrhagic events.5

Dabigatran etexilate is a new oral direct thrombin inhibitor that may provide an alternative to warfarin; it has the advantage of not requiring regular monitoring. In the multinational, Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study, 18 113 patients with non-valvular atrial fibrillation and at least one risk factor for stroke were randomised to one of two doses of dabigatran (110 mg or 150 mg, twice daily) or dose adjusted warfarin.6 After a median follow-up of two years, the rates of the primary outcome (stroke or systemic embolism) were similar to those for warfarin among patients assigned the lower dose but were lower among patients assigned the higher dose (1.11% v 1.71% per year; relative risk 0.66, 95% confidence interval 0.53 to 0.82; P=0.0001). Compared with warfarin, the annual rate of major bleeding was lower among patients assigned dabigatran 110 mg (2.71% v 3.36%; relative risk 0.80, 0.69 to 0.93; P=0.003) but similar among those assigned 150 mg. Dabigatran was associated with higher rates of myocardial infarction, but these were not statistically significant.7

The US Food and Drug Administration (FDA) was satisfied of the positive benefit to harm balance of dabigatran but failed to identify a subgroup of patients in which the benefit-harm profile was superior for the 110 mg dose compared with the 150 mg dose and consequently approved only the higher dose.8 However, both doses have been approved by other regulatory authorities, including the European Medicines Agency, which specifies 150 mg twice daily for patients under 80 years of age and 110 mg twice daily for those aged 80 and over or as an option when the thromboembolic risk is considered to be low and the risk of bleeding is high.9

Against this background, we describe a quantitative analysis of the trade-off between thrombotic and bleeding risks—events that have differential effects on life expectancy and quality of life—as a basis to guide clinicians’ prescribing. We also develop a health economic evaluation to estimate the cost effectiveness of dabigatran in patients with non-valvular atrial fibrillation, given the considerable uncertainty about its cost effectiveness in the UK healthcare setting.


Friday, December 23, 2011

 

dabigatran warfarin

Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial

  1. Jonas Oldgren, MD, PhD;
  2. Marco Alings, MD, PhD;
  3. Harald Darius, MD, PhD;
  4. Hans-Christoph Diener, MD, PhD;
  5. John Eikelboom, MD;
  6. Michael D. Ezekowitz, MD, PhD;
  7. Gabriel Kamensky, MD, PhD;
  8. Paul A. Reilly, PhD;
  9. Sean Yang, MSc;
  10. Salim Yusuf, MBBS, DPhil;
  11. Lars Wallentin, MD, PhD; and
  12. Stuart J. Connolly, MD,
  13. on behalf of the RE-LY Investigators

+ Author Affiliations

  1. From Uppsala Clinical Research Centre and Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Working Group on Cardiovascular Research, Utrecht, the Netherlands; Vivantes Klinikum Neukölln, Berlin, Germany; University Duisburg-Essen, Duisburg and Essen, Germany; Population Health Research Institute and McMaster University, Hamilton, Ontario, Canada; Lankenau Institute for Medical Research and the Heart Center, Wynnewood, Pennsylvania; University Hospital Bratislava, Bratislava, Slovakia; and Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut.

Abstract

Background: CHADS2 is a simple, validated risk score for predicting the risk for stroke in patients with atrial fibrillation not treated with anticoagulants. There are sparse data on the risk for thrombotic and bleeding complications according to the CHADS2 score in patients receiving anticoagulant therapy.

Objective: To evaluate the prognostic importance of CHADS2 risk score in patients with atrial fibrillation receiving oral anticoagulants, including the vitamin K antagonist warfarin and the direct thrombin inhibitor dabigatran.

Design: Subgroup analysis of a randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00262600)

Setting: Multinational study setting.

Patients: 18 112 patients with atrial fibrillation who were receiving oral anticoagulants.

Measurements: Baseline CHADS2 score, which assigns 1 point each for congestive heart failure, hypertension, age 75 years or older, and diabetes mellitus and 2 points for stroke.

Results: Distribution of CHADS2 scores were as follows: 0 to 1—5775 patients; 2—6455 patients; and 3 to 6—5882 patients. Annual rates of the primary outcome of stroke or systemic embolism among all participants were 0.93% in patients with a CHADS2 score of 0 to 1, 1.22% in those with a score of 2, and 2.24% in those with a score of 3 to 6. Annual rates of other outcomes among all participants with CHADS2 scores of 0 to 1, 2, and 3 to 6, respectively, were the following: major bleeding, 2.26%, 3.11%, and 4.42%; intracranial bleeding, 0.31%, 0.40%, and 0.61%; and vascular mortality, 1.35%, 2.39%, and 3.68% (P < 0.001 for all comparisons). Rates of stroke or systemic embolism, major and intracranial bleeding, and vascular and total mortality each increased in the warfarin and dabigatran groups as CHADS2 score increased. The rates of stroke or systemic embolism with dabigatran, 150 mg twice daily, and of intracranial bleeding with dabigatran, 150 mg or 110 mg twice daily, were lower than those with warfarin; there was no significant heterogeneity in subgroups defined by CHADS2 scores.

Limitation: These analyses were not prespecified and should be deemed exploratory.

Conclusion: Higher CHADS2 scores were associated with increased risks for stroke or systemic embolism, bleeding, and death in patients with atrial fibrillation receiving oral anticoagulants.


Wednesday, December 21, 2011

 

STROKE BEROERTE

Summary and Comment

Poststroke Blood Pressure Affects Risk for Recurrent Stroke

Risk was elevated with low and high systolic BP.

Risk for a first ischemic stroke is generally proportional to the level of systolic blood pressure (BP), but optimal poststroke BP for prevention of recurrent stroke is less clear. To examine this issue, researchers conducted a post hoc analysis of data from a previously published secondary prevention study that involved about 20,000 patients (mean age, 66; two thirds men) with recent noncardioembolic ischemic stroke (JW Cardiol Aug 27 2008).

The original study addressed the role of various antiplatelet regimens, and BP was managed by investigators at their discretion. Patients were assessed several times during a mean follow-up of 2.5 years, during which the risk for recurrent stroke was about 8%. Compared with patients who had low-normal systolic BP (120–129 mm Hg), risk for recurrent stroke was elevated in patients whose mean systolic BP during the study was very low (<120 mm Hg; 29% relative increase), high (140–149 mm Hg; 23% increase), or very high (≥150 mm Hg; 108% increase); risk with high-normal systolic BP (130–139 mm Hg) was similar to that with low-normal BP. These analyses were adjusted for clinical and demographic factors.

Comment: These post hoc analyses are sufficiently strong to support a recommendation to maintain systolic BP in the normal range (120–139 mm Hg) –– but not lower — in stroke patients. However, rigorous prospective studies to confirm this conclusion are warranted.

Thomas L. Schwenk, MD

Dr. Ovbiagele is an Associate Editor for Journal Watch Neurology but was not involved in the selection or summarization of this article.

Published in Journal Watch General Medicine December 20, 2011


Tuesday, December 20, 2011

 

rivaroxaban Xarelto Warfarin


Het grote voordeel voor de trombosepatiënten is dat er niet meer routinematig gemonitord hoeft te worden, de regelmatige injecties onnodig zijn en er niet meer noodzakelijk een dieet gevolgd moet worden. In plaats daarvan hoeven de patiënten slechts eenmaal per dag een tabletje te nemen.

Xarelto is in 27 lidstaten toegelaten voor trombosebeen en hartritmestoornissen, maakt farmaceut Bayer bekend. Volgens specialisten vervalt daarmee niet alleen voor trombosepatiënten een enorme belasting, maar ook is deze eenmaal daagse pil ‘single drug’ voor het gezondheidszorgsysteem een lastenverlichting.

In ons land worden ongeveer 41.000 Nederlanders jaarlijks getroffen door een beroerte, ook wel herseninfarct genoemd. Meer dan 216.000 mensen leven met de gevolgen van een beroerte. Patiënten met de hartritmestoornis boezemfibrilleren hebben een vier tot vijfvoudig verhoogd risico op het krijgen van een herseninfarct. In ons land lijden 300.000 mensen aan boezemfibrilleren, wat kan leiden tot gevaarlijke bloedstolsels.

Het middel Xarelto kwam bij wereldwijd onderzoek naar voren als een medicijn dat voordelen biedt ten opzichte van het vaak voorgeschreven middel Warfarine aan patiënten met boezemfibrileren. Aan deze studie deden ruim 14.000 patiënten in 45 landen mee. Vanuit Nederland waren twintig ziekenhuizen betrokken.



Saturday, December 17, 2011

 

zout hoge bloeddruk sodium intake

Hypertension for December 15, 2011

SUMMARY AND COMMENT

Sodium Excretion of >7 g or <3 g Daily Is Associated with Elevated Cardiovascular Morbidity

December 13, 2011 | Thomas L. Schwenk, MD | General Medicine

By comparison, higher potassium excretion was associated with lower stroke risk.

Reviewing: O'Donnell MJ et al. JAMA 2011 Nov 23/30; 306:2229

Whelton PK. JAMA 2011 Nov 23/30; 306:2262

Free Full-Text Article

Summary and Comment

Sodium Excretion of >7 g or <3 g Daily Is Associated with Elevated Cardiovascular Morbidity

By comparison, higher potassium excretion was associated with lower stroke risk.

The WHO recommends daily sodium intake of less than 2 g, based on relatively short trials in which the effect of sodium intake on blood pressure was assessed. In this study, researchers analyzed data for 28,880 patients in two international clinical trials of an angiotensin-receptor blocker; most patients (mean age, 67; 70% men) had histories of myocardial infarction, stroke, hypertension, or diabetes. People with congestive heart failure (CHF), decreased renal function, or uncontrolled hypertension were excluded. Mean daily sodium excretion (a surrogate for sodium intake) was 4.77 g, and daily potassium excretion was 2.19 g.

At 5 years, a composite outcome of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for CHF occurred in 4729 patients. Patients with urinary sodium excretion of 4 to 6 g daily had the lowest risk for the composite outcome. Risk was higher by 21%, 16%, 15%, and 49% for patients with daily excretion of <2 g, 2–3 g, 7–8 g, and >8 g, respectively. Compared with patients who had daily potassium excretion of <1.5 g, risk for stroke was 32% lower in those with excretion of >3 g. These analyses were adjusted for numerous clinical and demographic factors.

Comment: This J-shaped relation between sodium intake and cardiovascular outcomes conflicts with current recommendations to limit daily sodium intake to 2 g. However, an editorialist is unconvinced and believes that randomized trials are needed to account for confounding caused by preexisting disease and risk factors. The small number of patients with low sodium intake — 3% of the total sample had urinary excretion <2 g daily — also tempers the results. Consuming a diet high in natural foods and low in processed foods would result in a lower sodium–potassium ratio –– which could be more important than the actual intake levels.

Thomas L. Schwenk, MD

Published in Journal Watch General Medicine December 13, 2011


 

dabigatran aspirine warfarin

December 12, 2011 (San Diego, California) — The use of aspirin reduces the risk of recurrent venous thromboembolism (VTE) by more than half when compared with placebo, according to the results of a new study [1]. Investigators say the reduction in VTE risk, which was achieved without an increased risk of bleeding, makes aspirin an attractive treatment option for the extended prevention of recurrent VTE once oral anticoagulation has been stopped.

"Patients with a first episode of VTE usually receive initial therapy with heparin, which is given for five to seven days, and then they are switched over to oral anticoagulants," lead investigator Dr Cecilia Becattini (University of Perugia, Italy) told heartwire . "Oral anticoagulant therapy [with vitamin-K antagonists] is not very practical, as it requires laboratory monitoring and medical visits for adjustments. More important, there is the potential for harmful bleeding complications with warfarin, which can occur in about 3% of patients."

The past couple of years have seen the emergence of more anticoagulants for VTE, including the US Food and Drug Administration approval of rivaroxaban (Xarelto, Bayer/Johnson & Johnson) for prevention of deep venous thrombosis (DVT) in the setting of knee- or hip-replacement surgery. Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) has been approved in Europe for the prevention of VTE events in adult patients who have undergone elective hip- or knee-replacement surgery, while edoxaban (Lixiana, Daiichi Sankyo), another direct factor Xa inhibitor, is approved in Japan. Data from the RECOVER trial also showed that the new anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) was effective when used in the VTE setting, and it is currently approved for use in Europe.

"There are a lot of new agents out there that don't require laboratory monitoring, and some of these new oral anticoagulants have already been approved for use in patients with venous thromboembolism," said Becattini. "But again, they are anticoagulants, and while they are effective, the risk of bleeding complications is not zero."

In this study, known as WARFASA, which was presented at the American Society of Hematology 2011 Annual Meeting, the researchers tested whether the use of aspirin therapy was more effective than placebo in reducing the risk of recurrent VTE in patients treated with warfarin for six to 18 months following the first idiopathic VTE. After the initial treatment with warfarin, the drug was stopped, and 205 patients were randomized to 100 mg aspirin once daily and 197 patients to placebo.

During the two-year study period, recurrent symptomatic VTE occurred in 28 patients in the aspirin arm and 43 patients in the placebo group (6.6% per patient-year vs 11.2% per patient-year, respectively). In multivariate analysis, aspirin reduced the risk of recurrent VTE 42% (hazard ratio 0.58; 95% CI 0.36–0.93) compared with placebo. The risk of major bleeding and clinically relevant nonmajor bleeding was identical in the aspirin- and placebo-treated patients, with one major bleed and three clinically relevant bleeds reported in both groups. There was no significant difference in mortality.

Not as Efficacious, But Not as Risky

To heartwire , Becattini said that the bleeding risk with aspirin is 10-fold lower than that of other oral anticoagulants, and this study shows that putting a patient on aspirin extended therapy lowers the risk of recurrence without any significant increase in bleeding. It is a practical, low-cost option for clinicians and patients, even though it is not as efficacious for the reduction of recurrent VTE as other agents.

"You have to consider that in clinical trials, dabigatran and rivaroxaban showed an 80% to 90% reduction in the risk of venous thromboembolism, which is about double what we found with aspirin," she said. "These are the newer agents, but we don't yet know everything about their potential side effects. As well, there is the issue of cost."

After a three- or six-month treatment course with oral anticoagulants, Becattini said her center typically evaluates the risk for recurrent VTE by assessing conditions that were present at the time of the first event, such as trauma or surgery. Recurrent VTE can occur in as many as one in five patients in the two-year period following the withdrawal of oral anticoagulants.

"In cases that were associated with transient risk factors, we know the risk of a second venous thromboembolism is very low," she said. "So after three or six months, oral anticoagulants are usually discontinued. After the first episode, we'll stop the drugs and advise the patient about symptoms, telling them to come back to the hospital at the first sign something might be wrong.


Thursday, December 15, 2011

 

gewichtsverlies, pancreatitis

Question

An 86-year old patient in a senior living center has lost 34 pounds in the past 6 months. She claims her appetite is good, and no medical problems are apparent. How should I approach the evaluation of weight loss in this elderly patient?

Response from Barbara Resnick, PhD
Professor, University of Maryland; Nurse Practitioner, a Continuing Care Retirement Community, Baltimore, Maryland

Unexplained weight loss or losing weight without trying is often, but not always, associated with an underlying medical disorder. Loss of a few pounds is rarely a cause for concern in an older individual. A provider should be concerned, however, about unexplained weight loss over a 6-month period of 10 pounds (4.5 kg), weight loss of more than 5% of the patient's body weight, or weight loss that is persistent despite interventions.

The first thing to check when evaluating weight loss is whether the patient is eating a sufficient number of calories to maintain body weight. A dietician can be of value if help is needed in making such a determination. If intake is inadequate, it is helpful to look for psychosocial factors or normal changes of aging that might be contributing to reduced dietary intake. Changes in smell and taste, nausea, constipation, poor oral health, functional changes that make shopping and cooking challenging, eating alone, and being unable to afford food are all factors associated with reduced intake. If the underlying problem is found to be poor intake, interventions should focus on increasing oral intake and calories. High calorie snacks and small frequent meals are reasonable options. Nutritional supplements (eg, Ensure®), if accessible and affordable, are another option. Dietary restrictions (eg, low sodium diets) should be eliminated.

When dietary intake seems to be adequate, the weight loss is more likely to be a consequence of disease. Numerous medical problems can cause or contribute to unexplained weight loss (Table).

Table. Diseases Associated With Weight Loss

Addison disease
Cancer
Celiac disease
Chronic obstructive pulmonary disease
Crohn disease
Dementia
Depression
Diabetes
Heart failure
HIV/AIDS
Hypercalcemia
Thyroid disease
Parkinson disease
Peptic ulcer
Tuberculosis
Ulcerative colitis
Irritable bowel disease
Clostridium difficile


Causes include undiagnosed celiac disease, thyroid disorders, malignancies, dementia, depression, and diabetes. A comprehensive history and physical will guide the search for an underlying cause of the weight loss. History taking should particularly explore possible signs and symptoms that may indicate an underlying clinical problem such as cough, nausea, constipation, or pain. The physical exam should look for lymphadenopathy, breast changes, or thyroid changes. Laboratory tests should be ordered to evaluate for infection, anemia, electrolyte imbalances, and renal disease.

Treatment involves addressing the underlying cause for the unintentional weight loss (improving management of blood glucose in diabetes, treating depression, etc) and work to increase oral intake. If no improvement in weight occurs, then the patient should be re-evaluated with respect to the level of energy that is being expended (eg, is in the patient acutely ill or wandering excessively?) If no additional cause can be identified, consideration of pharmacologic management with appropriate medications to increase weight can be considered.


 

vitamine D

Question

How should vitamin D supplementation be managed in these specific populations?

Response from Darrell Hulisz, PharmD
Associate Professor, Case Western Reserve University School of Medicine; Clinical Specialist in Family Medicine, University Hospitals, Case Medical Center, Cleveland, Ohio

A previous Ask the Experts column written by Dr. Darrell Hulisz, "Which Is Better: Vitamin D2 or D3?", generated many readers' questions. Dr. Hulisz answers these questions below in a follow-up column.

Vitamin D is essential for adequate intestinal absorption of calcium. Chronic vitamin D deficiency can decrease serum calcium and can trigger a compensatory release of parathyroid hormone (PTH).[1,2] This may produce secondary hyperparathyroidism, resulting in the mobilization of calcium from bone and a reduction in bone mineral density (BMD).[2,3] Chronic vitamin D deficiency can lead to muscle weakness and increase the risk for osteoporotic fractures, falls, rickets, and osteomalacia.[2,4,5] In light of the recent attention given to vitamin D deficiency, several questions arise regarding supplementation in special populations.

What form of vitamin D is recommended in chronic kidney disease?

Vitamin D is produced endogenously in the skin and converted to active metabolites in the liver and kidney. Upon exposure to ultraviolet irradiation, provitamin D3 (7-dehydrocholesterol) in the skin is converted to previtamin D3, which is then isomerized to vitamin D3 (cholecalciferol). Vitamin D3, whether cutaneously formed or obtained in the diet as cholecalciferol, is subsequently hydroxylated in the liver to 25-hydroxyvitamin D (25-OH VD). This is the major circulating form of vitamin D that is assayed to detect deficiency.[1]

A subsequent hydroxylation of 25-OH VD occurs in the kidney to form 1,25-dihydroxyvitamin D, the major biologically active form of vitamin D, also known as calcitriol.[1,2] Thus, in the setting of severe chronic kidney disease (CKD), formulations of calcitriol may be preferred over vitamin D2 and D3 to treat deficiency because the terminal hydroxylation occurs in the kidney.

In the setting of CKD it is important to estimate glomerular filtration rate (GFR) and to determine serum 25-OH VD, calcium, phosphorous, and intact PTH levels when choosing the most optimal regimen. Supplementation of vitamin D plays a major role in the prevention of secondary hyperparathyroidism in patients with CKD.[6-8] According to clinical practice guidelines from the National Kidney Foundation, the preferred form of supplementation is guided by serum 25-OH VD levels, stage of kidney failure, and presence or absence of secondary hyperparathyroidism.[9] Before and during supplementation, both serum calcium and phosphorous levels should be drawn every 3 months. If levels of these minerals rise, vitamin D supplementation may need to be withheld or the dosage modified.[9]

In the presence of secondary hyperparathyroidism, which usually begins in stage 3 or 4 of CKD (GFR 30-59 mL/min and 15-29 mL/min, respectively), the preferred agent for supplementation is an activated vitamin D sterol (eg, calcitriol or paricalcitol). Supplementation should begin when serum levels of 25-OH VD fall below 30 ng/mL. The vitamin D sterol dose depends on the serum levels of 25-OH VD, PTH, calcium, and phosphorus. Likewise, in stage 5 of CKD (GFR < 15 mL/min and patients treated with hemodialysis or peritoneal dialysis), an activated vitamin D sterol is also preferred in lieu of vitamin D2 or D3.[9]

However, in the absence of secondary hyperparathyroidism, as is often the case in patients with GFR > 60 mL/min or only mild renal impairment, either oral vitamin D2 or D3 can be used. Studies indicate that vitamin D2 (ergocalciferol) is much less potent and has a shorter duration of action than D3 (cholecalciferol) and that vitamin D3 more effectively raises 25-OH VD levels.[10-13] Thus, cholecalciferol is preferred in patients with normal or mild renal impairment (GFR > 60 mL/min) with a normal intact PTH level.

What dose of cholecalciferol is suggested for preventing deficiency?

Several guidelines have been issued by national organizations that recommend varying amounts of vitamin D intake. A recent consensus report has been issued by the Institute of Medicine.[13] This guideline states that for most patients the recommended daily allowance of vitamin D should be 600-800 IU. However, increased amounts are necessary for treating known deficiency, such as 25-OH VD levels below 20 ng/mL. Supplemental vitamin D may become necessary in conditions in which risk factors for deficiency exist, such as living in extreme northern latitudes or lack of solar exposure, malabsorptive states, corticosteroid use, chronic dietary deficiency, and pregnancy. However, in these situations the dose of vitamin D is best guided by 25-OH VD levels.

What is the upper limit of vitamin D intake?

As a dietary supplement, patients should not exceed a daily amount of 4000 IU of vitamin D,[13] though higher doses may be needed temporarily to treat documented deficiency. Most cases of vitamin D toxicity have been associated with 25-hydroxyvitamin D levels greater than 88 ng/mL, a level that would necessitate a daily intake of 40,000 IU or more of vitamin D.[14] No significant changes from baseline in serum calcium levels or urinary calcium excretion were noted in patients given 4000 IU/day of vitamin D3 for up to 5 months.[15] In addition, cholecalciferol 100,000 IU administered to patients every 4 months for 5 years was found to be safe.[16]

Which vitamin D preparations are available in an oral liquid?

Vitamin D3 (cholecalciferol) is available as a concentration solution, ranging from 400 IU to 4000 IU per drop. Vitamin D2 (ergocalciferol) is also available in various liquid formulations, but it is commercially available in limited supply due to the superiority of cholecalciferol. Calcitriol, the activated vitamin D sterol, is available in a 1-µg/mL solution for oral administration.


 

pancreatitis chronic

From Current Opinion in Gastroenterology

Chronic Pancreatitis

Matthew J. DiMagno; Eugene P. DiMagno

Posted: 12/08/2011; Curr Opin Gastroenterol. 2011;27(5):452-459. © 2011 Lippincott Williams & Wilkins

Abstract and Introduction

Abstract

Purpose of review: We review important new clinical observations in chronic pancreatitis made in the past year.
Recent findings: Tropical pancreatitis associates with SPINK1 and/or CFTR gene mutations in approximately 50% of patients, similar to the frequency in idiopathic chronic pancreatitis. Corticosteroids increase secretin-stimulated pancreatic bicarbonate concentrations in autoimmune pancreatitis (AIP) by restoring mislocalized CFTR protein to the apical ductal membrane. Most patients with asymptomatic hyperenzymemia have pancreatic lesions of unclear significance or no pancreatic lesions. Common pitfalls in the use of diagnostic tests for exocrine pancreatic insufficiency (EPI) confound interpretation of findings in irritable bowel syndrome and severe renal insufficiency. Further study is needed to improve the accuracy of endoscopic ultrasonography (EUS) to diagnose chronic pancreatitis. Celiac plexus block provides short-term pain relief in a subset of patients.
Summary: Results of this year's investigations further elucidated the genetic associations of tropical pancreatitis, a reversible mislocalization of ductal CFTR in AIP, the association of asymptomatic pancreatic hyperenzymemia with pancreatic disorders, limitations of diagnostic tests for EPI, diagnosis of chronic pancreatitis by EUS and endoscopic pancreatic function testing and treatment of pain.

Introduction

Chronic pancreatitis is a progressive inflammatory and fibrotic disease of the pancreas with hallmark features of abdominal pain, malabsorption, malnutrition, diabetes mellitus and pancreatic calcifications. Currently, there is no definitive medical treatment for pancreatic inflammation, fibrosis or pain. In this review we focus on genetic associations of tropical pancreatitis, reversible mislocalization of ductal cystic fibrosis transmembrane conductance regulator (CFTR) in autoimmune pancreatitis (AIP), asymptomatic pancreatic hyperenzymemia, testing for exocrine pancreatic insufficiency (EPI), diagnosis of chronic pancreatitis by endoscopic ultrasound (EUS) and endoscopic pancreatic function testing (ePFT) and neuropathic pain of chronic pancreatitis.


Section 1 of 9

Monday, December 12, 2011

 

islam


Canadian security intelligence service

ARCHIVED: Commentary No. 30: The Rising Tide of Islamic Fundamentalism (I)

Commentary No. 30 has been archived.

Archived Content

Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.

Dr. Wm. Millward

April 1993
Unclassified

Abstract: The first of this two-part series examines the roots and goals of the Islamic revival that has been taking place in the Middle East and North Africa, and the differences between mainstream and militant Islamism. April 1993. Author: Dr. Wm. Millward.

Editors Note: This issue of Commentary, and the next, comprise a two-part series on Islamic Fundamentalism by Dr. Wm. Millward, a Strategic Analyst in the Analysis and Production Branch of CSIS. Dr. Millward is a frequent contributor to these pages, having written on Egypt and Iran, the Middle East Peace Process and the Gulf War.

In Part I of this series, Dr. Millward examines the genesis and objectives of the Islamic revival, and traces its two basic patterns-mainstream and militant Islamism-in the major countries of the Middle East and North Africa. Deliberately excluded from this discussion, and left to Part II, is the question of support for Islamism in what the author terms "A Growing Iranian Islamist Network". In the next issue of Commentary, Part II focuses on the nature of the threat.

Disclaimer: Publication of an article in the Commentary series does not imply CSIS authentication of the information nor CSIS endorsement of the author's views.


Introduction

Periodic resurgence is an integral part of several major religious traditions around the world. The spiritual and cultural renewal of many parts of the Islamic world in the second half of the 20th century is neither unique nor aberrant; it has not happened in a vacuum or under static conditions. It coincided with the demise of the colonial era, the retreat from empire, the liberation and independence of a host of former colonial states, the emergence of a world system centred on the United Nations, and more recently, the end of the cold war and the disappearance of the bipolar world of East and West.

In this broad context it is hardly surprising that many Muslims in the Middle East and elsewhere have felt the need to renew their commitment to the faith of their ancestors, and use it as a badge of identity in forging their own unique place in the modern world. In the process, the belief system called Islam has shown itself once again to be both a durable source of religious inspiration and spiritual guidance, as well as an ideological frame of reference capable of motivating its adherents towards self-assertion in political and social affairs.

A Question of Terminology

By an informal consensus, religious activism in the Muslim lands of the Middle East and North Africa has been labelled Islamic Fundamentalism, although most Muslims regard the term as a misnomer. Islam they say, unlike some other traditions, has always been characterized by its observance of fundamental principles. According to one Western academic, "The basic problem with the concept of fundamentalism is that it is an ethnocentric, militantly secularist categorization based on specious cross-cultural analogies." [Gregory Rose, Religious Resurgence and Politics in the Contemporary World, ed. Emile Sahliyeh, Albany: SUNY Press 1990. p. 219].

Responding to these objections, many writers have preferred to use the term "the Islamic movement" or simply "Islamism" and "Islamist" when referring to the revivalist and activist tendency among modern Muslims. Other commonly used terms are "intégrisme" and "radical political Islam". Whatever this phenomenon may be called, it is important to distinguish its several varieties and their chief characteristics as these are manifested in the major countries and principal centres of Muslim activism in the Middle East today. The Islamic movement is not a homogenous, unified and monolithic social phenomenon wherever it appears.

It can also seem inaccurate to speak of Islamic revival as if Islam had lost a good deal of its popularity and was, if not moribund, at least much weakened. On the contrary, it has continued through the ages to be popular, vibrantly alive, and expanding in numbers of adherents and territories represented. The Muslim community has continued to draw on Islam's deep reserves of spiritual nourishment to expand the frontiers of its presence through migration and missionary activity in Africa, Asia, Europe and the Americas. By most estimates, one billion people today consider themselves Muslim. Until recently it was the politicalface of Islam that was largely missing from the stage of public affairs. To speak of Islamic revival in recent years is to emphasize the growing desire of more Muslims to assert themselves on the plane of social and political action.

The Genesis of Islamic Revival

Broadly speaking, the Islamist trend among Muslims refers to those groups and movements in several countries which are seeking to establish, overtly or covertly, an Islamic government or state. The rationale for such an objective is that an Islamic government could be expected to enforce some if not most of the laws and rules of Islam (the Shari'a), including those relating to dress code, relations between the sexes, prohibition of alcohol and gambling, punishments for specified crimes, and restrictions on banking and interest. This would allow those who were citizens of such a state to live their lives more fully in accordance with the requirements of faith. It would facilitate the earning of spiritual credit and smooth the path to salvation. It would also give the Muslims concerned a larger say in determining their own affairs and make it easier to protect their interests in relations with outsiders.

Muslims calling for the revival of their religion and community have stressed the need for individual spiritual renewal by rededication to the moral and ethical prescriptions of their faith, and the need to revitalize the community at large, the collectivity of the Muslims in its physical and political context. Some prominent Islamist thinkers and activists during the last century have emphasized the internal and spiritual axis of renewal, while others have urged specific steps or courses of action to improve the social and political condition of Muslims at large.

In the heyday of modern imperialism, one of the most outspoken activists was Jamal al-Din al- Afghani (Asadabadi), a thinker and orator who preached a gospel of pan-Islam and anti-imperialism-primarily in the Sunni Muslim territories of India, Egypt and Turkey-as the most efficient means of renewing the condition of Middle East Muslims in his time (d.1897). Other successful exponents of the Islamist movement and message have urged reform in both the internal and external dimensions of the lives of Muslims. It is not widely known beyond the frontiers of Iran that one of the most popular tracts by the Ayatollah Ruhollah Khomaini was a booklet dealing with individual moral and spiritual renewal, with the imposing title The Greater Crusade: The Struggle with the Carnal Self.

If adherents to Islam are urged to focus their attention on their relationship to Allah as well as their relationships to one another and outsiders, Islamists argue that the Muslims generally have neglected the second half of their responsibility as believers, particularly in the sphere of politics and relations with non-Muslims. The prototype of Islamic government was the system put in place in 7th century Arabia by the prophet Muhammad before he died in 632 A.D., and perhaps some of its successor structures, usually referred to as the Caliphate.

Since the abolition of the Ottoman Caliphate in 1924-the last of these indigenous multinational Islamic governments-most Middle Eastern Muslims have been governed either by traditional tribal, feudal and monarchical rulers, or by modernized and at least partly secularized élites. The latter and most of the former, so the Islamists say, are more responsive to the interests of outside powers and forces, mostly non-Muslim, and not sufficiently attentive to the real needs of their subjects as Muslims. They must therefore be replaced by individuals who are more cognizant of the Islamic method in government and more likely to enable the majority population to live their lives in stricter conformity with the rules of Islam.

Objectives of Islamism

Most Islamist groups in the Middle East share the common objective of creating a truly Islamic society in which they can live under a régime governed by the rules of their faith as codified in Islamic law. For the extremists, the first condition for the achievement of this objective is the forcible overthrow of the current ruling élites in the Middle East, including such diverse régimes as the monarchies of Morocco and Saudi Arabia, the Emirates of Kuwait and the United Arab Emirates, and the secular governments of Algeria, Egypt and Tunisia. For Islamists in Israel and the Occupied Territories, it is the destruction of the state of Israel. The imported ideologies of communism, socialism, liberalism and nationalism are regarded, not completely without justification, as failures where they have been tried, and undesirable where they have not because they are either non-Islamic in their policies, or appear otherwise incompatible with Islamic norms.

The longer-term objective of the Islamist movement is the formation of a bloc of states whose governments apply Islamic law and practices. It hopes that such a bloc would be able, by itself or in alliance with other Third World nations, to change the rules of the international system, especially in relation to trade, and thus alter the current balance of economic and political power world-wide. In this sense, some consider their worldview threatening to the West. The Islamists believe that Islam can create, or help to create, a just political order at the international as well as at the state level. As for most Third World régimes, for them the current rules and regulations were laid down by the great powers to protect their own interests and to perpetuate their political and economic dominance.

Two Basic Patterns: Mainstream and Militant

Those Muslims who strive to establish an Islamic government or state can be divided in two groups according to the methods they employ to achieve their aims. The mainstream Islamist trend seeks to accomplish its aims by working within the existing rules and regulations of its members' respective societies. They are generally not opposed to a degree of political pluralism, to working within the system, to democratic participation, and acknowledge the interests and rights of minorities. These Islamists are generally pragmatic, and do not rule out the existence of a market economy. Mainstream Islamists include the Muslim Brothers of Egypt and Jordan, and some sections of Front islamique du salut-the Islamic Salvation Front (FIS) in Algeria, before it was deprived of its electoral victory, declared illegal and driven underground.

The second category of those who espouse the concept of an Islamic state are the militant, radical and revolutionary Islamists who are prepared to use violence in their efforts to unseat existing governments. This trend is best illustrated in Egypt by some elements of the Islamic Organizations (Jama'at Islamiyya) and by Islamic Jihad (Jihad Islami). The threat of Islamic fundamentalism which is widely publicized in the West these days comes exclusively from this group of Islamists. They generally reject the idea of pluralism, political or otherwise, decry democracy as non-Islamic, and repress ethnic, linguistic and religious minorities. Terrorist tactics are normally considered a legitimate tool in the arsenal available to such groups.

Social Support for Islamism

As general economic and social conditions remain static or decline in many parts of the Islamic Middle East, and governments remain incapable of dealing with these problems, the popularity of the Islamist outlook rises. Social and economic distress today-poverty and unemployment among the youth-feed the growing sense of disenchantment with the social and political status quo. The general economic malaise is exacerbated by the growing disparity between rich and poor. Régimes which count on imported social and economic programs-some dictated by the International Monetary Fund-to solve domestic problems are regarded as failures and un-Islamic.

In Algeria there is a substantial base of broad support for the Islamist current. Roughly 25 percent of the electorate, some three million people, voted for the Front islamique du salut (FIS) candidates in the federal election in the fall of 1991. Estimates of the number of committed, hard-core activists identified with FIS have varied from a handful to several hundred. Since the organization was declared illegal and severely repressed, the number of those who are now prepared to use violence to achieve their goals has substantially increased. The Algerian military is considered a bastion of opposition to the Islamists; while this assumption may be quite safe with regard to the higher ranks, many observers worry about the junior officers and lower ranks, which are thought to contain Islamist sympathizers whose loyalty to the current régime may be soft. Severe state repression is believed to have increased sympathy for the Islamists, even in intellectual circles.

In Lebanon, Hizballah is a religious, military and, since its participation in elections in the summer of 1992, a political force. Its primary constituency is the Shi'a population of the northern Biqa' valley, along with several villages in the Jabal 'Amil region in south Lebanon. The Shi'ites in Lebanon number 1.2 million, the largest religious group-41 percent-in a population of less than three million. Hizballah does not represent all the Shi'i Muslims of Lebanon but competes with the much more moderate, and numerically stronger, AMAL organization which it tries to radicalize, albeit with only limited success. The two groups were involved in a bitter three-year struggle that terminated in a peace accord in 1990 sponsored by their patrons in Tehran and Damascus. Hizballah candidates elected to the Lebanese parliament are believed to have drawn support from some Christian voters as well.

As for the membership of Hamas and Palestine Islamic Jihad, they represent a cross-section of all classes in the Occupied Territories of the West Bank and Gaza Strip. The 417 men from these two groups deported in December 1992 by Israel into south Lebanon give some indication of the people who support the Islamic movement in the territories. They are described as "ardent Islamists". Among them were several imams or spiritual guides. The militants included young students, labourers, shopkeepers and small traders, mechanics and a few professionals, mostly physicians and engineers. Some observers estimate that support for these militant Islamic groups in the Occupied Territories is running as high as 40 percent of the adult population.

In Egypt, the government has gone on the offensive against the Islamic militants, whose activities have long since spread from Upper Egypt to the capital. The Minister of the Interior, Abdel Halim Musa, in a press release in early February, claimed that in the preceding year religious extremists had killed 34 members of the police and security forces, military and civilian. [al-Hayat, February 6, 1993. p.7] Estimates of the number of militants active in Egypt vary between 10,000 and 30,000. Whatever the real number, it is in fact quite small as a percentage of total population. The mainstream Islamists of the Muslim Brotherhood are far more numerous than their extremist counterparts with perhaps as many as two million members and hundreds of thousands-if not millions-of sympathizers. A high percentage of Brotherhood members belong to the professional classes.

There is little prospect that economic and political conditions are going to improve in Algeria or Egypt or the Occupied Territories. An Islamist-oriented régime may well come to power in Algeria in the medium term. Another possible scenario is that growing Islamic extremism coupled with an increasingly harsh government response will lead to social fragmentation and anarchy in Algeria. In Egypt, although the government is under increasing pressure from Islamic militants, and is responding in kind, it is unlikely that an Islamic government will come to power in the next three to five years. As the level of tension between the authorities and their Islamist opponents rises, the possibility that a new round of conflict could spark a crisis increases proportionately. In the interim Egyptian officials will expend greater effort to step up the dialog with the Islamists and try to ensure that domestic and foreign policies continue along the path of gradual Islamization. As in Algeria, so in Egypt, the military is concerned with preserving its relative position in the social hierarchy and would therefore not approve the establishment of an Islamist-based government at this stage.

Saudi Arabia: Fundamentalist-Yes; Islamist-Yes and No

In a special sense the Kingdom of Saudi Arabia is the quintessential fundamentalist Islamic state. In addition to its role as the custodian of Islam's two sacred sanctuaries at Mecca and Medina, the kingdom is said to represent the religious tradition in its most pristine or puritanical version, Wahhabism. This is not to be confused with "orthodoxy". Defenders of the current political system in the kingdom argue that it still reflects today the ideals of the first Islamic revolution begun two and a half centuries ago with the formation of an alliance between the fundamentalist preacher Muhammad b. Abd al-Wahhab and the tribal chieftain, Muhammad b. Sa'ud, and completed with the conquest of Hijaz and the holy cities by their descendants Abd al-Aziz b. Saud and his supporters in 1924.

Critics on the other hand ridicule such claims and point out that since the discovery of oil and the acquisition of vast wealth, the monarchy has ceased to defend the interests of the Muslims at large and become dependent on non-Muslim power for its survival. Proof of this is the role played by Saudi Arabia in the Gulf crisis. The mere presence on the sacred soil of Arabia of nearly half a million non-Muslim combatants, albeit far removed from the two holy sanctuaries, for the purpose of defending the kingdom from Saddam and ultimately driving him from Kuwait, was a highly symbolic illustration of this dependence.

An Islamic, if not an Islamist, opposition in Saudi Arabia operates on three fronts. One is the Sunni populist and radical fundamentalist sentiment which was expressed in the takeover of the Grand Mosque in Mecca in December of 1979. This trend appears to have been eliminated since the incident was put down. The second source of opposition comes from that sector of the population, roughly 7 percent and located almost entirely in the Eastern province, who are Shi'a by rite, and have been subject to incessant propaganda from their fellow sectarians in Iran ever since the Islamic revolution. They seek full rights for Shi'a citizens, not state power. A third focus of opposition comes from many professional religious scholars who oppose the existing political system in the kingdom chiefly because of its dependence on the West. The institution of the ulama and the power it exercises in Saudi Arabia is tightly controlled by the government. It is unlikely that the dissident ulama will become a source of threat to the Saudi regime in the foreseeable future, but their presence behind the scenes will be a reminder to the government that some institutionalized forum for the expression of dissent is an urgent desideratum.

Increasing Organization: A Fundamentalist International?

The concept of organization and structure has been implicit in the Islamic faith and community from its inception. As a universal creed designed to accommodate humanity at large, even the earliest Muslims had to give their attention to the needs of new converts and the requirements of an expanding community. With the annual gathering of the believers in performance of the ritual obligation of pilgrimage, there is a sense in which the idea of the congress or annual general meeting was built into the system. But the universal caliphate was never coterminous with all the territory occupied by Muslims after the death of the Prophet. Power and control was frequently disputed from the periphery to the centre, and once the last Islamic empire of the Ottomans began to decline and fragment, the concept of structure and organization in the Islamic community became a more local and particular concern.

From the point of view of the Islamists, the transnational structures and organizations of the Muslim world have been dominated too long by those states which are subservient to foreign interests. The network of organizations and bodies with representatives in other Muslim states in the region has been controlled from the outset by the wealthy states of the peninsula, particularly Saudi Arabia. Through such groups as WAMY (World Assembly of Muslim Youth) and WML (World Muslim League) the peninsula states distribute funds for Muslim causes elsewhere, promote regular conferences and study groups, and attempt to defend Muslim interests and set the agenda for the Muslim world in its domestic and international settings.

The Jidda-based OIC (Organization of the Islamic Conference) is the most important Islamic body for discussing matters of foreign relations between Muslim states and international problems affecting Muslim interests. The Satanic Verses/Salman Rushdie issue was debated in the OIC. The same body is currently the forum for discussion of the Islamic dimension to the conflicts in the former Yugoslavia, Somalia, the West Bank and Gaza, and others. The OIC has not yet, however, been able to galvanize its members into taking joint action on issues.

Nonetheless, the concept of a "fundamentalist international" has occasioned widespread attention and an appreciable degree of discomfort and fear in the West. In this post cold-war era, some would even see it as having replaced communism as a major threat to world peace and security. We will turn the discussion toward the nature of this perceived threat in the subsequent issue (#31) of Commentary.


Commentary is a regular publication of the Analysis and Production Branch of CSIS. Inquires regarding submissions may be made to the Chairman of the Editorial Board at the following address:

The views expressed herein are those of the author, who may be contacted by writing to:

CSIS
P.O.Box 9732
Postal Station T
Ottawa, Ontario K1G 4G4
Fax: 613-842-1312


ISSN 1192-277X
Catalogue JS73-1/30


Saturday, December 10, 2011

 

statins

&

From Journal of the American Geriatrics Society

The Cholesterol Conundrum

John E. Morley, MB, BCh

Posted: 11/27/2011; J Am Geriatr Soc. 2011;59(10):1955-1956. © 2011 Blackwell Publishing


Abstract and Introduction

Introduction

Twenty-one years ago, Fran Kaiser and I published an editorial in this journal entitled "Cholesterol can be lowered in older persons. Should we care?"[1] This editorial was written in response to a series of epidemiological articles suggesting that, in old persons, low cholesterol was associated with greater total mortality. In this issue of the Journal, Newson and colleagues[2] found that higher total cholesterol and non-high-density lipoprotein cholesterol (HDL-C) in older persons was associated with a lower risk of noncardiovascular and total mortality. In part, this was attributable to a lower risk of cancer deaths.

One reason for the association between low cholesterol and mortality is that low cholesterol is associated with weight loss. Epidemiological studies have found that intentional or unintentional weight loss is associated with greater mortality.[3] Although the authors adjusted their analysis for body mass index (BMI), many overweight persons lose weight while their BMI remains high. Many reasons have been suggested for why weight loss may increase mortality, including occult or mild disease, loss of bone and muscle mass, loss of adipose stem cells, inappropriate medication dosing, and release of fat-soluble toxins into the circulation.

Another possibility is that some components of non-HDL-C may be protective against disease and that persons who survive into old age are more likely to be enriched for these protective elements. Low-density lipoprotein cholesterol LDL-C consists of a triglyceride-enriched, small, dense LDL that the arteries preferentially take up and is readily oxidized and a large, buoyant LDL.[4] This large LDL is nonatherogenic and is one of the factors associated with exceptional longevity.[5, 6] Increases in large LDL are associated with lower levels of the cholestryl ester transfer protein (CETP) and greater frequency in the homozygosity of the 1405 valine allele of CETP (VV genotype).

The correlation between low cholesterol and frailty may further explain the relationship with cholesterol reverse epidemiology in older persons.[7] Frailty is strongly associated with subsequent mortality[8] and with high cytokine levels and weight loss, both of which would lower cholesterol.


Section 1 of 3

 

dabigatran warfarin


From News Alerts > Heartwire

FDA Investigating Serious Bleeding Events With Dabigatran

Michael O'Riordan



December 7, 2011 (Rockville, Maryland) — The US Food and Drug Administration (FDA) announced today that it is now investigating postmarketing reports of serious bleeding events in patients taking dabigatran etexilate (Pradaxa, Boehringer Ingelheim) [1].

"FDA is working to determine whether the reports of bleeding in patients taking Pradaxa are occurring more commonly than would be expected, based on observations in the large clinical trial that supported the approval of Pradaxa," according to the drug safety communication issued by the agency.

That large clinical trial is RE-LY. As reported previously by heartwire , rates of fatal bleeding were numerically lower with the higher dose tested in the trial--150 mg twice daily--at 0.23% per year (230 per 100 000 patient-years) compared with warfarin at 0.33% per year (330 per 100 000 patient-years). Life-threatening bleeds were more common, numerically, in the 150-mg group than in the 110-mg group tested in the trial. The 110-mg dose was not approved by the FDA, although it is on other worldwide markets.

Bleeding events with dabigatran have already prompted safety advisories in Japan and Australia and have led to labeling updates in Europe and the US focusing on the need for monitoring renal function. In November, Boehringer Ingelheim confirmed that between March 2008 and October 31, 2011 there were 260 fatal bleeding events worldwide.

The FDA said it will inform the public and clinicians about any new information about bleeding risks when it becomes available. In the meantime, the agency said it believes the anticoagulant provides an important health benefit when used as directed and that patients taking dabigatran should not stop taking the drug without talking to their doctor.

The FDA also noted that physicians should report adverse events or side effects related to dabigatran use to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.


Thursday, December 08, 2011

 

Af aspirine


Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable

  1. Stuart J. Connolly, MD;
  2. John W. Eikelboom, MBBS;
  3. Jennifer Ng, MSc;
  4. Jack Hirsh, MD;
  5. Salim Yusuf, MD;
  6. Janice Pogue, MSc, MA;
  7. Raffaele de Caterina, MD, PhD;
  8. Stefan Hohnloser, MD; and
  9. Robert G. Hart, MD,
  10. on behalf of the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators

+ Author Affiliations

  1. From McMaster University, Hamilton, Ontario, Canada; Gabriele d'Annunzio University, Chieti, Italy; and Goethe University, Frankfurt, Germany.

Abstract

Background: Adding clopidogrel to aspirin therapy reduces stroke in patients with atrial fibrillation (AF) but increases hemorrhage.

Objective: To quantify the net benefit of adding clopidogrel to aspirin therapy, accounting for differences in clinical significance between ischemic and hemorrhagic events.

Design: Observational cohort study to assign the relative weighting of events and post hoc analysis of randomized trial data to assess net benefit of dual antiplatelet therapy in the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) clinical trials.

Setting: Global randomized clinical trial.

Patients: 10 041 patients with AF, 7554 of whom were not candidates for warfarin therapy.

Measurements: Ischemic events (ischemic stroke or myocardial infarction) and hemorrhagic events (hemorrhagic stroke or subdural or extracranial bleeding), weighted by the hazard ratio for death (or death or disability) after an event relative to death (or death or disability) after ischemic stroke. The net clinical benefit of dual antiplatelet therapy in the ACTIVE A trial participants was defined as the sum of weighted event incidence with dual antiplatelet therapy subtracted from the sum of weighted event incidence on control treatment, expressed as ischemic stroke equivalents prevented per 100 patients years.

Results: Adding clopidogrel to aspirin therapy prevented 0.57 ischemic stroke equivalent (95% CI, −0.12 to 1.24) per 100 patient-years of treatment when weighted by hazard for death after ischemia or hemorrhage and 0.67 ischemic stroke equivalent (CI, −0.03 to 1.18) when weighted by death or disability after ischemia or hemorrhage.

Limitation: No attempt was made to relate deaths used for weighting to events; disability data were missing for more than one half of patients.

Conclusion: Adding clopidogrel to aspirin therapy resulted in a modest net benefit among patients with AF for whom warfarin was unsuitable. The benefit would probably be clinically relevant for some patients, but estimates could not exclude the possibility of either no benefit or very small harm in this population

Tuesday, December 06, 2011

 

IgG4 pancreatitis

Autoimmun Rev. 2010 Jul;9(9):591-4. Epub 2010 May 10.

The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity.

Source

First Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan. htakahas@sapmed.ac.jp

Abstract

IgG4-related disease is a distinct clinical entity, whose characteristic features are the following; Serum IgG4 is prominently elevated, IgG4-positive plasma cells infiltrate in involved tissues, various mass-forming lesions with fibrosis develop in a timely and spatial manner and the response to corticosteroids is prompt and good. IgG4-related diseases mainly target two organs. One is the pancreas (autoimmune pancreatitis; AIP), and the other comprises the lacrimal and salivary glands, the clinical phenotype is Mikulicz's disease (MD). MD has long been considered a manifestation of Sjögren's syndrome (SS). However, we noticed several clinical differences in case of MD from SS; no deflection of female sex differences, mild sicca syndrome, good response to corticosteroids, no positivity of anti-SS-A/SS-B antibodies. In addition, elevated level of serum IgG4 and abundant infiltration of plasma cells expressing IgG4 were reported in MD patients. Those are common features of IgG4-related diseases. MD often coexisted with IgG4-related diseases such as AIP, retroperitoneal fibrosis, and IgG4-associated nephropathy. Based on those findings, it has been considered to recognize IgG4-related diseases including MD as a new clinical entity. The etiology of IgG4-related systemic diseases remains to be elucidated. It is necessary to accumulate and analyze larger data from patients worldwide.


This page is powered by Blogger. Isn't yours?